Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ALECSAT in newly diagnosed glioblastoma
NCT02799238Phase 2Completed
- Sponsor
- CytoVac
- Start
- Mar 2016
- Primary completion
- Nov 2019
- Modality
- Prophylactic Vaccines, Therapeutic Vaccines, Adoptive Cell Transfer
- Countries
- 1
01
Overview
A Phase 2 trial of alecsat in glioblastoma (GBM), sponsored by CytoVac. Started Mar 2016; status: completed.
02
Drugs
alecsat
03
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on NCT02799238.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02799238.